In the video below, Fool analysts David Williamson and Max Macaluso discuss drugmaker Dendreon (NASDAQ: DNDN) as a possible takeover target in 2013.
While hope of a buyout has diminished as Dendreon's struggles mounted, the possibility still exists. However, there is one additional hurdle that might keep big pharma away from Dendreon, which investors are not talking about.
